NO20082165L - Bifenylderivater som modulatorer av spenningsstyrte ionekanaler - Google Patents

Bifenylderivater som modulatorer av spenningsstyrte ionekanaler

Info

Publication number
NO20082165L
NO20082165L NO20082165A NO20082165A NO20082165L NO 20082165 L NO20082165 L NO 20082165L NO 20082165 A NO20082165 A NO 20082165A NO 20082165 A NO20082165 A NO 20082165A NO 20082165 L NO20082165 L NO 20082165L
Authority
NO
Norway
Prior art keywords
modulators
voltage controlled
biphenyl derivatives
ion channels
controlled ion
Prior art date
Application number
NO20082165A
Other languages
English (en)
Norwegian (no)
Inventor
Esther Martinborough
Nicole Zimmermann
Aarti Sameer Kawatkar
Timothy Neubert
Andreas Termin
Danielle Lehsten
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20082165L publication Critical patent/NO20082165L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
NO20082165A 2005-10-12 2008-05-13 Bifenylderivater som modulatorer av spenningsstyrte ionekanaler NO20082165L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72568605P 2005-10-12 2005-10-12
PCT/US2006/040156 WO2007047474A2 (en) 2005-10-12 2006-10-12 Biphenyl derivatives as modulators of voltage gated ion channels

Publications (1)

Publication Number Publication Date
NO20082165L true NO20082165L (no) 2008-07-09

Family

ID=37836784

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082165A NO20082165L (no) 2005-10-12 2008-05-13 Bifenylderivater som modulatorer av spenningsstyrte ionekanaler

Country Status (15)

Country Link
US (2) US7683083B2 (de)
EP (1) EP1934191B1 (de)
JP (1) JP2009511599A (de)
KR (1) KR20080059292A (de)
CN (1) CN101365690A (de)
AT (1) ATE551333T1 (de)
AU (1) AU2006304283B2 (de)
CA (1) CA2624831A1 (de)
ES (1) ES2383090T3 (de)
IL (1) IL190632A0 (de)
NO (1) NO20082165L (de)
NZ (1) NZ567570A (de)
RU (1) RU2008118350A (de)
WO (1) WO2007047474A2 (de)
ZA (1) ZA200803704B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
JP2008540539A (ja) 2005-05-10 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャンネルの調節因子としての二環系誘導体
MX2007014486A (es) * 2005-05-16 2008-02-12 Vertex Pharma Derivados biciclicos como moduladores de canales ionicos.
CA2622076A1 (en) * 2005-09-09 2007-03-15 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of voltage gated ion channels
CN101365690A (zh) * 2005-10-12 2009-02-11 沃泰克斯药物股份有限公司 作为电压门控离子通道调控剂的联苯衍生物
EP1948597A1 (de) * 2005-10-21 2008-07-30 Vertex Pharmaceuticals Incorporated Derivate zur modulation von ionenkanälen
CN101365686A (zh) * 2005-12-21 2009-02-11 沃泰克斯药物股份有限公司 作为离子通道调节剂的杂环衍生物
JP2010528035A (ja) 2007-05-25 2010-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節物質およびその使用
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
JP2011503112A (ja) 2007-11-13 2011-01-27 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の処置のためのイオンチャンネルのモジュレーターとしての４（−３−（−２−（フェニル）モルホリノ）−２−オキソピロリジン−１−イル）−ｎ−（チアゾール−２−イル）ベンゼンスルホンアミド誘導体および関連化合物
JP2011503191A (ja) * 2007-11-13 2011-01-27 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとしての複素環誘導体
CN101978787A (zh) * 2008-04-30 2011-02-16 夏普株式会社 照明装置和显示装置
AU2009266979A1 (en) * 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
SMT201700256T1 (it) 2013-01-31 2017-09-07 Vertex Pharma Piridone ammidi come modulatori di canali del sodio
US20200270237A1 (en) * 2017-10-19 2020-08-27 Esteve Pharmaceuticals, S.A. New alkoxyamino compounds for treating pain and pain related conditions
CA3105748A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridazine compounds for inhibiting nav1.8
CA3105657A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
WO2020163236A1 (en) * 2019-02-04 2020-08-13 The General Hospital Corporation Treating long qt syndrome
JP7728367B2 (ja) 2021-06-14 2025-08-22 スコーピオン・セラピューティクス・インコーポレイテッド がんを処置するために使用され得る尿素誘導体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
WO2002039987A2 (en) 2000-11-14 2002-05-23 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
JP2005509677A (ja) * 2001-11-22 2005-04-14 ビオヴィトルム・アクチボラゲット １型１１−ベータ−ヒドロキシステロイドデヒヒドロゲナーゼの阻害剤
IL160630A0 (en) * 2001-11-22 2004-07-25 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR20060073930A (ko) * 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
MXPA06007077A (es) * 2003-12-19 2006-08-23 Pfizer Derivados de bencenosulfonilamino-piridin-2-ilo y compuestos relacionados como inhibidores de 11-beta-hidroxi esteroide deshidrogenasa tipo 1 para el tratamiento de diabetes y obesidad.
WO2006089871A2 (en) 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
CN101365690A (zh) * 2005-10-12 2009-02-11 沃泰克斯药物股份有限公司 作为电压门控离子通道调控剂的联苯衍生物

Also Published As

Publication number Publication date
CA2624831A1 (en) 2007-04-26
EP1934191B1 (de) 2012-03-28
KR20080059292A (ko) 2008-06-26
WO2007047474A2 (en) 2007-04-26
RU2008118350A (ru) 2009-11-20
CN101365690A (zh) 2009-02-11
US8236833B2 (en) 2012-08-07
AU2006304283A1 (en) 2007-04-26
IL190632A0 (en) 2008-11-03
US20100130548A1 (en) 2010-05-27
ES2383090T3 (es) 2012-06-18
NZ567570A (en) 2011-02-25
ATE551333T1 (de) 2012-04-15
ZA200803704B (en) 2009-09-30
EP1934191A2 (de) 2008-06-25
US20080113990A1 (en) 2008-05-15
JP2009511599A (ja) 2009-03-19
AU2006304283B2 (en) 2012-01-19
US7683083B2 (en) 2010-03-23
WO2007047474A3 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
NO20082165L (no) Bifenylderivater som modulatorer av spenningsstyrte ionekanaler
NO20081725L (no) Bicykliske derivater som modulatorer for spenningsaktiverte ione-kanaler
DK2089369T3 (da) 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
NO20076306L (no) Bicykliske derivater som modulatorer av ionekanaler
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
WO2008112715A3 (en) Novel agents of calcium ion channel modulators
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
BRPI0408026A (pt) Quinazolinas úteis como moduladores de canais de ìon
NO20060518L (no) Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
WO2008147797A3 (en) Ion channel modulators and methods of use
WO2009035818A8 (en) Compounds that modulate intracellular calcium
HN2009001112A (es) Inhibidores de la actividad de la akt
WO2007145704A3 (en) Gemcitabine combination therapy
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
MX2010002028A (es) Metodos y composiciones para modular celulas t.
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
CR9869A (es) Compuestos activos en ppar
WO2010027875A3 (en) Compounds that modulate intracellular calcium
NO20060202L (no) Pyrrolodihydroisokinoliner som PDE-10-inhibitorer
WO2008014199A3 (en) Sulfonyl compounds which modulate the cb2 receptor
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
ATE538084T1 (de) Bicyclische 1,4-retigabin-analoga als kaliumkanalhemmer
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application